Page 204 - EJMO-9-1

Eurasian Journal of Medicine and
Oncology
Cost-effectiveness of nivolumab+chemo for gastric/GEJ cancer

Table 2. Baseline values, ranges, and distributions for sensitivity analysis
Variable (Group: CPS >5 Baseline value Range Distribution Mean Standard References
patients) Minimum Maximum deviation
Parameter survival distribution
Log-logistic PFS of N+C Shape=1.648147 - - - - - Model fitting
Scale=8.546154
Log-logistic OS of N+C Shape=1.6508 - - - - - Model fitting
Scale=14.4888
Log-logistic PFS of C Shape=1.6508 - - - - - Model fitting
Scale=14.4888
Log-logistic OS of C Shape=1.7398 - - - - - Model fitting
Scale=10.546
Risk for main adverse events
Nivolumab plus chemotherapy group
Neutropenia 0.15 0.12 0.18 Beta 0.15 0.03 13
Neutrophil count decreased 0.11 0.088 0.132 Beta 0.11 0.022 13
Anemia 0.07 0.056 0.084 Beta 0.07 0.014 13
Diarrhea 0.05 0.04 0.06 Beta 0.05 0.01 13
Chemotherapy group
Neutropenia 0.06 0.048 0.072 Beta 0.06 0.012 13
Neutrophil count decreased 0.03 0.024 0.036 Beta 0.03 0.006 13
Anemia 0.02 0.016 0.024 Beta 0.02 0.004 13
Diarrhea 0.03 0.024 0.036 Beta 0.03 0.006 13
Health utility scores
Utility of PFS 0.797 0.6376 0.9564 Beta 0.797 0.1594 26
Utility of PD 0.577 0.4616 0.6924 Beta 0.577 0.1154 26
Drug cost, $/per cycle
Nivolumab-3w 9,957.15 7,965.72 11,948.58 Gamma 9,957.15 1,991.43 Drugs
Oxaliplatin-3w 521.82 417.456 626.184 Gamma 521.82 104.364 Drugs
Capecitabine-3w 183.3 146.64 219.96 Gamma 183.3 36.66 Drugs
Nivolumab-2w 6,638.1 5,310.48 7,965.72 Gamma 6,638.1 1,327.62 Drugs
Oxaliplatin-2w 341.19 272.952 409.428 Gamma 341.19 68.238 Drugs
Leucovorin-2w 185.184 148.1472 222.2208 Gamma 185.184 37.0368 Drugs
Fluorouracil-2w 43.62624 34.90099 52.35149 Gamma 332.148 66.42962 Drugs
Radiotherapy 8,998.72 6,636.09 13,160.22 Gamma 8,998.72 1,799.744 27
Surgery 20,982 10,490 41,960 Gamma 20,982 4,196.4 28
Paclitaxel 726.57 581.256 871.884 Gamma 726.57 145.314 Drugs
Docetaxel 215.595 172.476 258.714 Gamma 215.595 43.119 Drugs
Carboplatin 165.51 132.408 198.612 Gamma 165.51 33.102 Drugs
Cisplatin 17.064 13.6512 20.4768 Gamma 17.064 3.4128 Drugs
Ramucirumab 143,731 114,984.8 172,477.2 Gamma 14,3731 2,8746.2 Drugs
Pembrolizumab 10,739.54 8,591.632 12,887.45 Gamma 10,739.5 2,147.908 Drugs
Expenditures on main AEs, ($)
Neutropenia 1,043 834.4 1,251.6 Gamma 1,043 208.6 29
Neutrophil count decreased 466 372.8 559.2 Gamma 466 93.2 30
(Cont’d...)

Volume 9 Issue 1 (2025) 196 doi: 10.36922/ejmo.7075